Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorMohsen Pourazizi
About this trial
The goal of this clinical trial is to learn if oral melatonin can enhance visual acuity and central macular thickness in central serous chorioretinopathy (CSCR) in adults. The main questions it aims to answer are:
1. How does melatonin affect central macula thickness in CSCR? 2. How does melatonin affect visual acuity in CSCR? Researchers will compare placebo (a look-like substance that contains no drug) to see if melatonin works to treat CSCR.
Participants will:
1. Take melatonin or placebo twice a day for one month 2. Visit the clinic after finishing a course of treatment, and 1 and 3 months after that for visual acuity assessment and tests 3. Keep a diary of their symptoms
Eligibility criteria
Qualifiers
Patients whose diagnosis of central serous chorioretinopathy is confirmed based on clinical and imaging criteria within the past 6 weeks
Patients with minimum age of 18 years old
Consent to participate in the study
Disqualifiers
A history of vitrectomy
A history of laser surgery in the eye being studied in the past 3 months
A history of anti-VEGF injection in the eye being studied in the past 3 months
History of patient suspicious for choroidal neovascularization (CNV)
Trial design
Treatments tested in this trial
- melatonin 3mg
- Placebo Drug
Treatment groups
48 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Mohsen Pourazizi
Lead sponsor
Isfahan University of Medical Sciences
Sponsor institution
Source ClinicalTrials.gov